Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACLX Arcellx	$64.69 -1.8%	$63.03	$47.86 ▼ $107.37	$3.63B	0.28	610,374 shs	478,234 shs
ADMS Adamas Pharmaceuticals	$8.22	$8.17	$4.02 ▼ $9.15	$376.37M	2.82	692,487 shs	N/A
BHVN Biohaven	$13.94 -1.2%	$17.15	$13.87 ▼ $55.70	$1.44B	0.91	1.28 million shs	2.40 million shs
EOLS Evolus	$9.20 -0.1%	$10.11	$8.67 ▼ $17.82	$593.82M	0.97	747,940 shs	1.12 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACLX Arcellx	-1.76%	+2.12%	+1.76%	-3.78%	+20.69%
ADMS Adamas Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
BHVN Biohaven	-1.20%	-5.80%	-6.00%	-41.11%	-60.50%
EOLS Evolus	-0.11%	-4.37%	-1.81%	-24.71%	-16.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACLX Arcellx	2.7712 of 5 stars	3.5	3.0	0.0	0.0	2.9	2.5	0.0
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	2.7709 of 5 stars	4.5	1.0	0.0	0.0	0.6	2.5	0.6
EOLS Evolus	4.0732 of 5 stars	3.5	0.0	0.0	3.5	3.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACLX Arcellx	3.07	Buy	$111.23	71.94% Upside
ADMS Adamas Pharmaceuticals	0.00	N/A	N/A	N/A
BHVN Biohaven	3.07	Buy	$58.46	319.38% Upside
EOLS Evolus	3.00	Buy	$23.75	158.15% Upside

Current Analyst Ratings Breakdown

Latest EOLS, ADMS, ACLX, and BHVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	BHVN Biohaven	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$68.00 ➝ $55.00
6/17/2025	ACLX Arcellx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$110.00
6/16/2025	ACLX Arcellx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$115.00
5/19/2025	BHVN Biohaven	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$54.00 ➝ $21.00
5/13/2025	BHVN Biohaven	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	BHVN Biohaven	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$61.00 ➝ $54.00
5/9/2025	ACLX Arcellx	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$133.00 ➝ $93.00
5/8/2025	EOLS Evolus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
4/28/2025	BHVN Biohaven	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $57.00
4/24/2025	BHVN Biohaven	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/17/2025	EOLS Evolus	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACLX Arcellx	$107.94M	33.03	N/A	N/A	$8.41 per share	7.69
ADMS Adamas Pharmaceuticals	$74.46M	5.05	N/A	N/A	($0.47) per share	-17.49
BHVN Biohaven	N/A	N/A	N/A	N/A	$4.19 per share	N/A
EOLS Evolus	$266.27M	2.23	N/A	N/A	$0.09 per share	102.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACLX Arcellx	-$107.35M	-$2.99	N/A	N/A	N/A	-211.46%	-35.27%	-22.73%	8/14/2025 (Estimated)
ADMS Adamas Pharmaceuticals	-$57.40M	-$1.70	N/A	N/A	N/A	-71.11%	N/A	-42.96%	N/A
BHVN Biohaven	-$846.42M	-$9.36	N/A	N/A	N/A	N/A	-257.07%	-164.01%	8/5/2025 (Estimated)
EOLS Evolus	-$50.42M	-$0.89	N/A	N/A	N/A	-20.40%	-759.04%	-20.14%	7/30/2025 (Estimated)

Latest EOLS, ADMS, ACLX, and BHVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	EOLS Evolus	-$0.09	N/A	N/A	N/A	$82.18 million	N/A
5/12/2025	Q1 2025	BHVN Biohaven	-$1.67	-$2.17	-$0.50	-$2.17	$1.25 million	N/A
5/8/2025	Q1 2025	ACLX Arcellx	-$0.84	-$1.13	-$0.29	-$1.13	$19.51 million	$8.13 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACLX Arcellx	N/A	4.93	4.93
ADMS Adamas Pharmaceuticals	21.25	4.53	4.17
BHVN Biohaven	N/A	2.33	2.33
EOLS Evolus	22.00	2.34	2.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACLX Arcellx	96.03%
ADMS Adamas Pharmaceuticals	69.97%
BHVN Biohaven	88.78%
EOLS Evolus	90.69%

Insider Ownership

Company	Insider Ownership
ACLX Arcellx	8.35%
ADMS Adamas Pharmaceuticals	18.90%
BHVN Biohaven	14.60%
EOLS Evolus	6.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACLX Arcellx	80	55.11 million	50.51 million	Optionable
ADMS Adamas Pharmaceuticals	138	45.79 million	37.13 million	Optionable
BHVN Biohaven	239	102.11 million	87.21 million	Optionable
EOLS Evolus	170	64.48 million	60.54 million	Optionable

EOLS, ADMS, ACLX, and BHVN Headlines

Recent News About These Companies

Evolus (NASDAQ:EOLS) Shares Down 5.5% After Insider Selling

June 17, 2025 | marketbeat.com

David Moatazedi Sells 16,582 Shares of Evolus, Inc. (NASDAQ:EOLS) Stock

June 16, 2025 | marketbeat.com

Insider Selling: Evolus, Inc. (NASDAQ:EOLS) Insider Sells 111,323 Shares of Stock

June 16, 2025 | marketbeat.com

Evolus, Inc. (NASDAQ:EOLS) Shares Bought by Assenagon Asset Management S.A.

June 15, 2025 | marketbeat.com

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 13, 2025 | businesswire.com

Evolus, Inc. Common Stock (EOLS) Stock Forecasts

June 11, 2025 | ca.finance.yahoo.com

Evolus (NASDAQ:EOLS) Shares Gap Up After Insider Buying Activity

June 11, 2025 | marketbeat.com

Evolus, Inc. (NASDAQ:EOLS) Director Buys $189,000.00 in Stock

June 11, 2025 | insidertrades.com

Insider Buying: Evolus, Inc. (NASDAQ:EOLS) Director Purchases 20,000 Shares of Stock

June 10, 2025 | marketbeat.com

Evolysse™ Recognized in 2025 Shape Skin Awards

June 10, 2025 | businesswire.com

Evolus (NASDAQ:EOLS) Stock Price Down 4.7% - Should You Sell?

June 9, 2025 | marketbeat.com

Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Jane Street Group LLC

June 8, 2025 | marketbeat.com

Evolus, Inc. (NASDAQ:EOLS) Holdings Lowered by Squarepoint Ops LLC

June 7, 2025 | marketbeat.com

Evolus (NASDAQ:EOLS) Trading 7.9% Higher - Here's Why

June 3, 2025 | marketbeat.com

Evolus Launches Second Product Line for Wrinkles

June 2, 2025 | ocbj.comO

Evolus Launches CFO Search Ahead of Beaver's Resignation

May 27, 2025 | marketwatch.com

Evolus CFO to Resign

May 27, 2025 | ocbj.comO

Evolus Announces Departure of its Chief Financial Officer

May 27, 2025 | businesswire.com

Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

May 24, 2025 | seekingalpha.com

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 16, 2025 | businesswire.com

Evolus, Inc. (NASDAQ:EOLS) Insider David Moatazedi Sells 15,787 Shares

May 16, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOLS, ADMS, ACLX, and BHVN Company Descriptions

Arcellx NASDAQ:ACLX

$64.69 -1.16 (-1.76%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$64.76 +0.06 (+0.10%)

As of 07/1/2025 06:14 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Adamas Pharmaceuticals NASDAQ:ADMS

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Biohaven NYSE:BHVN

$13.94 -0.17 (-1.20%)

Closing price 07/1/2025 03:59 PM Eastern

Extended Trading

$14.44 +0.51 (+3.62%)

As of 05:40 AM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Evolus NASDAQ:EOLS

$9.20 -0.01 (-0.11%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$9.20 0.00 (-0.05%)

As of 05:27 AM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time